Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate
Vaxcyte will host a webcast and conference call on October 5, 2026 at 8:00 a.m. ET to present topline data from OPUS-1, the pivotal adult Phase 3 trial of VAX-31, its 31-valent pneumococcal conjugate vaccine candidate. VAX-31 is the company's lead asset and the broadest-spectrum PCV candidate in the clinic, designed to prevent invasive pneumococcal disease and pneumonia. It is also in a Phase 2 infant program.
Key figures
- Drug Name
- VAX-31
- Phase Of Trial
- Phase 3
- Trial name
- OPUS-1
- Webcast datetime
- October 5, 2026 8:00 a.m. ET
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.